Although varieties of North American English have come in for a good deal of linguistic scrutiny in recent years, the vast majority of published works have dealt with American rather than Canadian English. This volume constitutes a welcome addition to our linguistic knowledge of English-speaking Canada. While the focus of the volume is primarily synchronic, several of the dozen papers it contains offer a diachronic perspective on Canadian English. Topics range from general issues in Canadian lexicography and orthography to sociolinguistic studies of varieties of English spoken in all major geographical areas of the country: Atlantic Canada, Ontario, Quebec and the West. A theme common to many of the articles is the relationship of Canadian English to American varieties to the south.

Written by a former professional baseball player whose career was ended with an injury to his pitching arm in the middle of his third season, Focus on the Good Stuff is filled with passion, authenticity, and humor. Author Mike Robbins offers a step-by-step program with exercises for overcoming negative influence and obstacles, creating a truly grateful approach to life, and establishing an environment that can support success and peace of mind.

Education Policy Analysis 2005-2006 includes articles on achieving quality, equity and efficiency in higher education; the growing international market in higher education; valuing teachers; formative assessment and gender differences and mathematics: performance.

Presents an overview of Pakistan, covering its landscape, climate, people, government, economy, transportation system, education, healthcare, culture, religion, and recreation.

Smoking is a greater cause of death and disability than any single disease, says the World Health Organisation. According to their figures, it is responsible for approximately five million deaths world-wide every year. Tobacco smoking is a known or probable cause of approximately 25 diseases including cancer, heart attacks and strokes. The WHO says that its impact on world health is still not fully assessed. This new book offers leading new research from around the globe.

Work is central to a whole host of other rights, providing the basis for a safe, healthy and dignified existence. For members of minorities, indigenous peoples and other marginalized groups such as migrants, however, it is all too often an arena of discrimination, abuse and exploitation. From poor pay and dangerous working conditions to a lack of basic labour protections and barriers to promotion, the challenges they face are wide ranging and often entangled in other areas of inequality, such as access to education. This volume brings together thematic chapters and case studies that explore different dimensions of work-related exclusion, from the legacy of colonialism in today’s economy to the persistence of slavery and caste-based discrimination. While abuse and exploitation are often rooted in specific local histories and social contexts, the increasingly interlinked nature of globalization has meant that companies, governments and consumers are now complicit in forced labour and other rights violations taking place elsewhere. A truly fair and inclusive labour market would deliver a wide range of economic and societal benefits, creating opportunities for marginalized workers to participate fully in the formal economy with the same rights, protections and support as those enjoyed by others, guaranteed by international law. Beyond this, however, it has the potential to deliver lasting change to the situation of minorities, indigenous peoples and migrants worldwide, ensuring they receive a proper share of any economic gains in their countries and can participate fully in public life.

Malignant pleural mesothelioma (MPM) is a rare thoracic cancer that derives from the mesothelial cells of the pleura and is causally associated with exposure to asbestos. Because of its aggressiveness and resistance to therapies, MPM prognosis is extremely poor and the 5-year survival rate is approximately 10%. Despite its poor effectiveness, chemotherapy with cisplatin and pemetrexed has long remained the standard-of-care for upfront treatment with no second line therapy available. Recently, the approval of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) for the first-line treatment of unresectable MPM has marked a significant milestone, in particular for the non-epithelioid MPM subtype, which is more resistant to chemotherapy and associated with a poorer outcome. However, most MPM patients are still resistant to cancer therapies. Beyond histologic subtypes, recent studies have highlighted extensive genetic variation and gene expression deregulation both between and within MPM patients. This molecular heterogeneity highlights the need for a personalized treatment approach. Therefore, both multiple therapeutic options and predictive biomarkers that can guide clinical decision-making are urgently needed. Tumor cell immunogenicity and tumor microenvironment composition (TME) are the major determinants of the success of immunotherapy. Despite the low tumor mutational burden, recent studies indicate that chromoanagenesis and chromotripsis are molecular features of MPM. Since chromosomal instability can lead to the expression of neo-antigens, it could also influence the efficacy of immune checkpoint inhibitors (ICIs). The immunosuppressive TME is an additional important hurdle that limits the efficacy of immunotherapy. The combination of ICIs with strategies to boost anti-tumor immunity by restraining immunosuppressive myeloid cells or by reprograming “cold tumor” into “hot tumor” is an active area of research. This Research Topic aims to discuss recent advances in understanding and targeting MPM immune microenvironment for therapeutic purposes along with potential predictive biomarkers to select patients who most likely will respond to immunotherapies. We are interested in basic and clinical studies that explore the crosstalk between tumor and immune cells in order to highlight new molecular targets, approaches, and combination treatments to enhance anti-tumor immunity in MPM and assess potential predictive biomarkers of response to immunotherapy.